Compare CABR & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABR | IMNN |
|---|---|---|
| Founded | 2020 | 1982 |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5M | 10.8M |
| IPO Year | N/A | 2000 |
| Metric | CABR | IMNN |
|---|---|---|
| Price | $1.12 | $2.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 86.0K | 36.0K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $0.48 |
| 52 Week High | $1.65 | $9.32 |
| Indicator | CABR | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 59.87 | 19.78 |
| Support Level | $0.79 | N/A |
| Resistance Level | $1.32 | $3.24 |
| Average True Range (ATR) | 0.10 | 0.17 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 94.09 | 7.79 |
Caring Brands Inc is a wellness consumer products company. It offers several over-the-counter (OTC) and cosmetic consumer products. Its product pipeline includes a diverse products, such as hair loss treatments, eczema and psoriasis treatments, vitiligo solutions, a jellyfish sting protective suncare line, and women's sexual wellness products, catering to diverse health and wellness needs. It operates in a single segment.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.